 |
| 06/29/09 |
Science Magazine Spotlights 20 Years of CF Research An article in the June 19, 2009 issue of Science highlights several promising new CF therapies, including VX-770 and VX-809 developed by Vertex Pharmaceuticals, as part of a look back at key moments in CF research since the discovery of the CF gene 20 years ago.
|
 |
| 05/04/09 |
Cystic Fibrosis Foundation is Featured in The New Yorker The May 4th issue of The New Yorker magazine featured a major story about the efforts to cure cystic fibrosis. The story— “Open Channels”— focused exclusively on drugs in the Cystic Fibrosis Foundation’s pipeline that show promise in treating the underlying defect in cystic fibrosis.
|
 |
| 04/24/09 |
The New York Times Features: “A Brighter Outlook for Cystic Fibrosis Patients” The New York Times online published a series of stories today on cystic fibrosis called "A Brighter Outlook for Cystic Fibrosis Patients." The series includes an expert Q&A with Dr. Preston Campbell, executive vice president for medical affairs of the CF Foundation.
|
 |
| 11/12/08 |
The New York Times Recognizes CF Foundation’s Pioneering Business Model
|
 |
| 09/15/08 |
Forbes -- "Patient Power" A story in Forbes highlights the Foundation’s progress in driving drug development for a rare disease. In the story, CF patient Emily Schaller says of the Foundation: "They're the reason I'm alive."
|
 |
| 04/03/08 |
BusinessWeek -- "A Healthy Gamble for Cystic Fibrosis" BusinessWeek online showcases the Foundation’s unique business model and its promising investments in pharmaceutical companies to develop drugs for cystic fibrosis.
|
 |
| 12/19/07 |
Pharmaceutical Approvals Monthly -- "Breath Of Fresh Air For Cystic Fibrosis Drug Pipeline" The December issue of Pharmaceutical Approvals Monthly, a leading publication for the biotech industry, highlights the success of the CF Foundation’s drug discovery and development pipeline.
|
 |
| 08/13/07 |
The Boston Globe -- "$22m to Help Develop Drug for Cystic Fibrosis" An Aug. 13 article in The Boston Globe announced the CF Foundation's new biotech collaboration with FoldRx Pharmaceuticals. The story describes the Foundation's agreement to pay FoldRx $22 million over five years to discover and develop new compounds to treat the core defect in CF.
|
 |
| 05/09/07 |
BioWorld Today -- "Model Changing, But Alliances with Nonprofits Still Valuable" The May 9 issue of BioWorld Today highlights the CF Foundation in an article about venture philanthropy and its role in developing drugs for orphan diseases.
|
 |
| 05/07/07 |
Chemical & Engineering News -- "Sowing Seeds of Cures" A cover story in the May 7 issue of Chemical & Engineering News prominently features the CF Foundation’s business model. The article describes how the Foundation's strategy of funding early-stage, high-risk drug research has successfully fueled a pipeline with nearly 30 promising therapies.
|
 |
| 02/13/06 |
USA Today -- "Maze of Cystic Fibrosis Is Getting a Little Clearer" USA Today published an article on February 13, 2006 that chronicled the CF Foundation’s multi-faceted approached to defeat cystic fibrosis, including the funding of more than 30 clinical trials since 1998.
|
 |
| 02/10/06 |
Parents -- "My Son Has Cystic Fibrosis" A pediatrician and mother of a young son with cystic fibrosis talks about coping with the disease.
|
 |
| 12/06/04 |
The New Yorker -- "The Bell Curve" The article discusses the importance of quality care and the impact care can have on patient health and well being and praises the Foundation for being far ahead of other organizations in measuring the performance of its practitioners and for keeping detailed records of patient outcomes.
|
 |
| 12/09/03 |
SmartMoney -- "Charity Checkup" The CF Foundation recognized as a leader among U.S. health/research charities for keeping its administrative costs to a minimum, while maximizing funds for medical programs.
|
 |
| 04/02/01 |
Forbes -- "Drug Money" Most disease foundations are passive grant-givers. The Cystic Fibrosis Foundation is a very different beast--more like a biotech financier."
|